PT - JOURNAL ARTICLE AU - Bell, Samira AU - Campbell, Jacqueline AU - Lambourg, Emilie AU - Watters, Chrissie AU - O’Neil, Martin AU - Almond, Alison AU - Buck, Katharine AU - Carr, Edward J AU - Clark, Laura AU - Cousland, Zoe AU - Findlay, Mark AU - Joss, Nicola AU - Metcalfe, Wendy AU - Petrie, Michaela AU - Spalding, Elaine AU - Traynor, Jamie P AU - Sanu, Vinod AU - Thomson, Peter AU - Methven, Shona AU - Mark, Patrick B AU - on behalf of the Scottish Renal Registry TI - The impact of vaccination on incidence and outcomes of SARS-CoV-2 infection in patients with kidney failure in Scotland AID - 10.1101/2022.01.05.22268785 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.05.22268785 4099 - http://medrxiv.org/content/early/2022/01/06/2022.01.05.22268785.short 4100 - http://medrxiv.org/content/early/2022/01/06/2022.01.05.22268785.full AB - Background Patients with kidney failure requiring kidney replacement therapy (KRT) are at high risk of complications and death following SARS-CoV-2 infection with variable antibody responses to vaccination reported. We investigated the effects of COVID-19 vaccination on incidence of infection, hospitalization and death of COVID-19 infection.Methods Study design was an observational data linkage cohort study. Multiple healthcare datasets were linked to ascertain all SARS-CoV-2 testing, vaccination, hospitalization, and mortality data for all patients treated with KRT in Scotland, from the start of the pandemic over a period of 20 months. Descriptive statistics, survival analyses and vaccine effectiveness were calculated.Results As of 19th September 2021, 93% (n=5281) of the established KRT population in Scotland had received two doses of an approved SARS-CoV-2 vaccine. Over the study period, there were 814 cases of SARS-CoV-2 infection (15.1% of the KRT population). Vaccine effectiveness against infection and hospitalization was 33% (95% CI 0-52) and 38% (95% CI 0-57) respectively. 9.2% of fully vaccinated individuals died within 28 days of a SARS-CoV-2 positive PCR test (7% dialysis patients and 10% kidney transplant recipients). This compares to <0.1% of the vaccinated Scottish population being admitted to hospital or dying death due to COVID19 during that period.Conclusions These data demonstrate a primary vaccine course of two doses has limited impact on COVID-19 infection and its complications in patients treated with KRT. Adjunctive strategies to reduce risk of both COVID-19 infection and its complications in this population are urgently required.Competing Interest StatementPBM reports grants from Boehringer Ingelheim; personal fees from Astellas, AstraZeneca, Janssen, and Novartis; and personal fees and nonfinancial support from Napp, Pharmacosmos, and Vifor outside the submitted work. SB reports personal fees from AstraZeneca outside the submitted work.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was deemed unnecessary according to Public Health Scotland Information Governance as this was analysis of routinely collected data. As the analysis used routinely collected and anonymized data, individual patient consent was not sought. Access and use of the data for the purpose of this work were approved following a Public Health Scotland information governance review of linking internal datasets. Only the Public Health Scotland analyst had access to the linked patient data which could only be accessed via an NHS secure network.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article cannot be shared publicly as they are held by Public Health Intelligence, Scotland. Data can be requested from the electronic Data Research and Innovation Service (eDRIS) team which are part of the Public Health Scotland Public Health Intelligence, Scotland through phs.edris@nhs.net.